- Home
- JHX vs RPRX Comparison
JHX vs RPRX Comparison
Compare JHX & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHX
- RPRX
- Stock Information
- Founded
- JHX 1888
- RPRX 1996
- Country
- JHX Ireland
- RPRX United States
- Employees
- JHX N/A
- RPRX N/A
- Industry
- JHX Building Materials
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- JHX Industrials
- RPRX Health Care
- Exchange
- JHX Nasdaq
- RPRX Nasdaq
- Market Cap
- JHX 13.6B
- RPRX 14.2B
- IPO Year
- JHX N/A
- RPRX 2020
- Fundamental
- Price
- JHX $23.58
- RPRX $30.74
- Analyst Decision
- JHX Buy
- RPRX Strong Buy
- Analyst Count
- JHX 5
- RPRX 5
- Target Price
- JHX $45.00
- RPRX $41.60
- AVG Volume (30 Days)
- JHX 1.8M
- RPRX 4.3M
- Earning Date
- JHX 05-19-2025
- RPRX 05-08-2025
- Dividend Yield
- JHX N/A
- RPRX 2.81%
- EPS Growth
- JHX N/A
- RPRX N/A
- EPS
- JHX 1.01
- RPRX 1.91
- Revenue
- JHX $3,910,900,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- JHX N/A
- RPRX $33.46
- Revenue Next Year
- JHX $6.75
- RPRX $4.44
- P/E Ratio
- JHX $24.01
- RPRX $16.41
- Revenue Growth
- JHX 1.60
- RPRX N/A
- 52 Week Low
- JHX $23.23
- RPRX $24.05
- 52 Week High
- JHX $43.57
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- JHX 24.32
- RPRX 35.44
- Support Level
- JHX $23.23
- RPRX $32.26
- Resistance Level
- JHX $24.78
- RPRX $34.14
- Average True Range (ATR)
- JHX 0.85
- RPRX 0.76
- MACD
- JHX -0.71
- RPRX -0.29
- Stochastic Oscillator
- JHX 3.54
- RPRX 11.78
About JHX James Hardie Industries plc (Ireland)
James Hardie is a manufacturer of fiber cement-based building products, selling primarily to the residential construction industry. North America is the primary geography, generating about 80% of group earnings. Here, it is the largest manufacturer of fiber cement, which is mainly used for exterior siding on houses. Businesses in Australia, New Zealand, and Europe, make up the rest of earnings.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.